FIELD: medicine.
SUBSTANCE: invention can be used for treating asthma by normalizing a score according to a questionnaire for assessing asthma in a patient. That is ensured by subcutaneous injection of benralizumab or its antigen-binding fragment 30 mg once every four weeks for twelve weeks. Then once in eight weeks. Patient's eosinophil count is at least 300 cells/mql. Questionnaire for assessing asthma is selected from a group consisting of an asthma control questionnaire (ACQ), an asthma control questionnaire (ACQ-6) and a questionnaire for assessing the quality of life in asthmatic patients (AQLQ).
EFFECT: invention provides normalizing a score according to a questionnaire for assessing asthma in a patient with asthma.
11 cl, 4 tbl, 10 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF NORMALIZING ASTHMA SYMPTOMS USING BENRALIZUMAB | 2020 |
|
RU2840902C2 |
| METHODS OF TREATMENT OR PREVENTION OF ASTHMA THROUGH ADMINISTRATION OF IL-4R ANTAGONIST | 2013 |
|
RU2801531C2 |
| DIAGNOSTIC AND THERAPEUTIC METHODS ASSOCIATED WITH TH2 INHIBITION | 2020 |
|
RU2832013C2 |
| TREATMENT AND INHIBITION OF INFLAMMATORY LUNG DISEASES IN PATIENTS WITH RISK ALLELES IN GENES ENCODING IL33 AND IL1RL1 | 2018 |
|
RU2776241C2 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
| HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING SPECIFIC GROUPS OF INDIVIDUALS | 2012 |
|
RU2721279C2 |
| COMBINATION | 2015 |
|
RU2744841C2 |
| DOSING STRATEGY REDUCING CYTOKINE RELEASE SYNDROME FOR CD3/C20 BISPECIFIC ANTIBODIES | 2019 |
|
RU2799529C2 |
| ANTIBODY AGAINST HUMAN INTERLEUKIN-4 ALPHA RECEPTOR, METHOD OF ITS PREPARATION AND ITS APPLICATION | 2021 |
|
RU2807060C1 |
| PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING AND/OR TREATING A DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF REDUCING OR LOSING ACTIVITY OF THE BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED COAGULATION FACTOR VIII | 2015 |
|
RU2721910C2 |
